Metronidazole: Clinical Overview
Primary Indications
Metronidazole is FDA-approved and guideline-recommended for treating trichomoniasis, bacterial vaginosis, amebiasis, and serious anaerobic bacterial infections 1. The drug demonstrates excellent efficacy against obligate anaerobes (excluding Actinomyces, Arachnia, and Propionibacterium) and specific protozoal infections 2.
FDA-Approved Indications 1:
Protozoal Infections:
- Symptomatic and asymptomatic trichomoniasis (including treatment of sexual partners)
- Acute intestinal amebiasis and amebic liver abscess
- Giardiasis
Anaerobic Bacterial Infections:
- Intra-abdominal infections (peritonitis, abscess, liver abscess)
- Skin and soft tissue infections
- Gynecologic infections (endometritis, tubo-ovarian abscess, post-surgical infections)
- Bacterial septicemia
- Bone and joint infections (adjunctive)
- CNS infections (meningitis, brain abscess)
- Lower respiratory tract infections (pneumonia, empyema, lung abscess)
Additional Clinical Uses:
- Bacterial vaginosis
- Clostridioides difficile infection (though newer guidelines now favor vancomycin or fidaxomicin)
Dosing Regimens
Trichomoniasis 3:
- Preferred: Metronidazole 2 g orally as single dose (90-95% cure rate)
- Alternative: Metronidazole 500 mg orally twice daily for 7 days
- Treatment failures: Re-treat with 500 mg twice daily for 7 days; if repeated failure, use 2 g once daily for 3-5 days
Bacterial Vaginosis 3:
- Non-pregnant: Metronidazole 500 mg orally twice daily for 7 days OR metronidazole gel 0.75%, one applicator intravaginally twice daily for 5 days
- Pregnant (high-risk, second trimester): Metronidazole 250 mg orally three times daily for 7 days (lower doses minimize fetal exposure)
Clostridioides difficile Infection:
Critical Update: The 2018 IDSA/SHEA guidelines represent a major shift from older recommendations 4:
- Initial episode (non-severe or severe): Vancomycin 125 mg orally 4 times daily for 10 days OR fidaxomicin 200 mg twice daily for 10 days is now preferred over metronidazole (strong recommendation)
- Metronidazole 500 mg orally 3 times daily for 10 days should only be used when vancomycin/fidaxomicin access is limited (weak recommendation) 4
- Avoid repeated or prolonged metronidazole courses due to cumulative neurotoxicity risk (strong recommendation)
- Fulminant CDI: Vancomycin 500 mg orally 4 times daily PLUS intravenous metronidazole 500 mg every 8 hours; add rectal vancomycin if ileus present 4
Anaerobic Infections 1:
- Typically initiated with IV formulation, then transitioned to oral therapy at physician discretion
- Standard adult dosing: 500 mg every 8 hours
Emerging Evidence on Dosing Intervals: Recent data suggests metronidazole dosed every 12 hours may be as effective as every 8 hours for intra-abdominal infections, with no difference in clinical cure rates 5, 6. However, this remains off-label and requires further validation through randomized controlled trials.
Absolute Contraindications 1
- Prior hypersensitivity to metronidazole or other nitroimidazole derivatives
- First trimester of pregnancy for trichomoniasis treatment specifically
Pregnancy Considerations:
- First trimester: Contraindicated for trichomoniasis; use clindamycin cream for bacterial vaginosis 7
- Second/third trimester: Can use metronidazole 2 g single dose for trichomoniasis OR 250 mg three times daily for 7 days for bacterial vaginosis 3
- Lower doses recommended in pregnancy to minimize fetal exposure 3
Adverse Effects
Common (Mild-Moderate) 8:
- Nausea, abdominal pain, diarrhea
- Metallic taste
- Generally well-tolerated
Serious (Rare) 8, 2:
- Neurotoxicity: Peripheral neuropathy, seizures, encephalopathy (particularly with prolonged/high-dose therapy)
- Optic neuropathy
- Reversible neutropenia
- Disulfiram-like reaction with alcohol consumption (absolute avoidance required)
Drug Interactions 9:
- Alcohol: Severe disulfiram-like reaction
- Disulfiram: Additive effects
- Warfarin: Enhanced anticoagulation effect
Long-term Concerns 2:
- Mutagenicity and carcinogenicity demonstrated in some animal models
- Human follow-up studies have not shown increased cancer incidence to date
- Risk-benefit assessment required; use only for approved indications
Critical Pitfall: Avoid repeated or prolonged courses due to cumulative and potentially irreversible neurotoxicity 4. This is particularly important for CDI, where vancomycin is now preferred.
Alternative Therapies 10
When metronidazole is contraindicated or inadvisable:
Trichomoniasis:
- Furazolidone
- Clotrimazole (topical)
- Nonoxynol-9
- Paromomycin
- Note: No truly effective oral alternatives exist in the U.S. 7
Bacterial Vaginosis:
- Clindamycin cream 2% intravaginally (preferred in first trimester pregnancy) 7
- Clindamycin 300 mg orally twice daily for 7 days
- Caution: Clindamycin vaginal cream in pregnancy associated with increased preterm deliveries 3
Giardiasis:
- Paromomycin
- Nitazoxanide
- Benzimidazole antihelminthics
C. difficile:
- Vancomycin 125 mg orally 4 times daily (now first-line) 4
- Fidaxomicin 200 mg twice daily
- Nitazoxanide
- Rifaximin (for recurrent disease after vancomycin)
- Fecal microbiota transplantation (for multiple recurrences)
Anaerobic Infections:
- Clindamycin (for most anaerobes)
- Beta-lactam/beta-lactamase inhibitor combinations
- Carbapenems
Key Clinical Pearls
Partner treatment is essential for trichomoniasis; instruct patients to avoid sexual contact until both partners complete therapy and are asymptomatic 7
HIV-positive patients receive identical treatment regimens 7
Metronidazole gel is ineffective for trichomoniasis (cannot achieve therapeutic levels in urethra/perivaginal glands); only oral formulations work 3
Follow-up unnecessary for asymptomatic patients after trichomoniasis treatment 3
For CDI, vancomycin or fidaxomicin is now strongly preferred over metronidazole for initial episodes 4
Pharmacokinetics: Excellent tissue penetration including CNS; well-absorbed orally; detectable at bactericidal levels in blood/saliva within 1 hour 9, 2
Minimal impact on normal flora: Specifically targets anaerobes without disturbing aerobic commensal bacteria 2
Resistance is rare but can occur with T. vaginalis; most resistant strains respond to higher doses 3